文献速递肺外科

非小细胞肺癌手术切除前需进行诱导治疗后肺功能复测

Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer.
PubMed 文献 · J Thorac Cardiovasc Surg · 2021-12-23

该回顾性研究纳入1001例接受诱导治疗后肺切除的病理I-III期非小细胞肺癌患者,按诱导前后DLCO状态分组。多变量分析显示,诱导前正常而诱导后受损的DLCO状态与呼吸系统并发症(OR 2.29)及院内并发症(OR 2.83)风险增加相关。结论认为诱导后DLCO降低可能预测围手术期结局,重复肺功能检测可能识别高危患者。

要点

  • 诱导前DLCO正常而诱导后受损与呼吸系统并发症风险增加相关(OR 2.29)。
  • 该DLCO状态也与院内并发症风险增加相关(OR 2.83)。
  • 新辅助治疗类型与传统化疗相比未增加并发症风险。

核心结论

  • 诱导后DLCO降低可能预测围手术期结局。
  • 重复肺功能检测可能识别发病或死亡风险较高的患者。

研究设计与样本

  • 回顾性综述了1001例接受诱导治疗后肺切除的病理I、II或III期非小细胞肺癌患者。
  • 肺功能按美国外科医师学会肿瘤学组主要标准定义:DLCO≥50%为正常,DLCO<50%为受损。
  • 患者按诱导前后DLCO状态分为5个亚组:正常-正常、正常-受损、受损-正常、受损-受损及仅诱导前(无诱导后肺功能检测)。
  • 采用多变量逻辑回归量化DLCO分类与二分类终点之间的关系。

主要发现

  • 多变量分析中,正常-受损DLCO状态与呼吸系统并发症风险增加相关(比值比2.29 [95%CI 1.12-4.49];P=0.02)。
  • 正常-受损DLCO状态与院内并发症风险增加相关(比值比2.83 [95%CI 1.55-5.26];P<0.001)。
  • 与传统化疗相比,新辅助治疗类型与并发症风险增加无关。

关键数值与推荐

  • DLCO≥50%定义为正常,DLCO<50%定义为受损(美国外科医师学会肿瘤学组主要标准)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Pretreatment-predicted postoperative diffusing capacity of the lung for carbon monoxide (DLCO) has been associated with operative mortality in patients who receive induction therapy for resectable non-small cell lung cancer (NSCLC). It is unknown whether a reduction in pulmonary function after induction therapy and before surgery affects the risk of morbidity or mortality. We sought to determine the relationship between induction therapy and perioperative outcomes as a function of postinduction pulmonary status in patients who underwent surgical resection for NSCLC. METHODS: We retrospectively reviewed data for 1001 patients with pathologic stage I, II, or III NSCLC who received induction therapy before lung resection. Pulmonary function was defined according to American College of Surgeons Oncology Group major criteria: DLCO ≥50% = normal; DLCO <50% = impaired. Patients were categorized into 5 subgroups according to combined pre- and postinduction DLCO status: normal-normal, normal-impaired, impaired-normal, impaired-impaired, and preinduction only (without postinduction pulmonary function test measurements). Multivariable logistic regression was used to quantify the relationship between DLCO categories and dichotomous end points. RESULTS: In multivariable analysis, normal-impaired DLCO status was associated with an increased risk of respiratory complications (odds ratio, 2.29 [95% CI, 1.12-4.49]; P = .02) and in-hospital complications (odds ratio, 2.83 [95% CI, 1.55-5.26]; P < .001). Type of neoadjuvant therapy was not associated with an increased risk of complications, compared with conventional chemotherapy. CONCLUSIONS: Reduced postinduction DLCO might predict perioperative outcomes. The use of repeat pulmonary function testing might identify patients at higher risk of morbidity or mortality.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Connolly JG, Fiasconaro M, Tan KS, et al. Postinduction therapy pulmonary function retesting is necessary before surgical resection for non-small cell lung cancer. J Thorac Cardiovasc Surg. 2021. PMID: 35086669. doi:10.1016/j.jtcvs.2021.12.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。